The Biostatistics and Data Management Core for the University of Texas M.D. Anderson Cancer Center Melanoma P01 will be a comprehensive, multi-lateral resource for designing basic science and clinical experiments, developing innovative statistical methodology, statistical analysis, and aiding in the publication of research generated by the program project. The Biostatistics and Data Management Core will incorporate sound experimental design principles within each project that will increase the clarity and enhance interpretability of study results. Each project will be provided with tailored analyses, accompanied by novel statistical development as necessary, to reveal apparent and hidden relationships among data. The Core will provide expertise in the management of the clinical data through data quality control, data security, and assurance of patient confidentiality. The Biostatistics and Data Management Core will collaborate with all project investigators to facilitate the timely publication of all data collected under the P01 research program. The main objectives of the Biostatistics and Data Management Core are:
Specific Aim 1 : To provide guidance in the design and conduct of basic science experiments and clinical trials arising from the ongoing research of the P01.
Specific Aim 2 : To provide the innovative statistical modeling, simulation techniques, and data analyses needed by the Projects, Developmental Projects, and other Cores to achieve their Specific Aims.
Specific Aim 3 : To ensure that the results of all Projects are based on well-designed experiments and are appropriately interpreted.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA128913-05
Application #
8382654
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$91,307
Indirect Cost
$90,090
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Peng, Weiyi; Chen, Jie Qing; Liu, Chengwen et al. (2016) Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov 6:202-16
Singh, Manisha; Overwijk, Willem W (2015) Intratumoral immunotherapy for melanoma. Cancer Immunol Immunother 64:911-21
Lande, Roberto; Chamilos, Georgios; Ganguly, Dipyaman et al. (2015) Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. Eur J Immunol 45:203-13
Meller, Stephan; Di Domizio, Jeremy; Voo, Kui S et al. (2015) T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. Nat Immunol 16:970-9
Singh, Manisha; Khong, Hiep; Dai, Zhimin et al. (2014) Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol 193:4722-31
Hailemichael, Yared; Overwijk, Willem W (2013) Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard. Oncoimmunology 2:e24743
Hailemichael, Yared; Dai, Zhimin; Jaffarzad, Nina et al. (2013) Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med 19:465-72
Radvanyi, Laszlo; Pilon-Thomas, Shari; Peng, Weiyi et al. (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter. Clin Cancer Res 19:5541
Yang, Yan; Liu, Chengwen; Peng, Weiyi et al. (2012) Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 120:4533-43
Zhang, Minying; Maiti, Sourindra; Bernatchez, Chantale et al. (2012) A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy. Clin Cancer Res 18:4733-42

Showing the most recent 10 out of 22 publications